Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Europe seen weaker as more rate hikes loom

Mon, 12th Dec 2022 07:44

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPE SEEN WEAKER AS MORE RATE HIKES LOOM (0740 GMT)

European shares are set to kick off a macro-packed week on the back foot, tracking Friday's late losses on Wall Street and weakness earlier in Asia, where spreading COVID cases in China added to the downbeat mood.

EuroSTOXX50, DAX and FTSE futures fell between 0.3 and 0.5%, while the MSCI's broadest index of Asia-Pacific shares outside Japan fell 1.3%. U.S. futures meanwhile pointed to softer start on Wall Street.

On the European corporate news front, shares in London Stock Exchange will be in focus after Microsoft agreed to take 4% in the UK exchange operator as part of deal to migrate the bourse operator's data platform into the cloud.

Eyes also on Sanofi after the French health group dropped plans to bid for Horizon Therapeutics, while in Italy, Tod's founder ditched plans to delist the shoemaker after a buy-out that didn't meet a key threshold.

Still in M&A, Superdry is another one to watch after the Sunday Times reported CEO and founder Julian Dunkerton has held talks with private equity firms about a possible buyout.

HUNKERING DOWN (0659 GMT)

Just as China faces a testing time over its dramatic COVID-19 policy pivot, financial markets are on full alert ahead of interest rate decisions coming out this week from the world's top central banks.

Initial market enthusiasm over China's easing of its stringent "zero-COVID" measures has now switched to worries over a wave of infections likely disrupting the economy.

European stock markets are set for a weaker start on Monday, dragged by declines in Asian stocks, with the spotlight on a series of central bank meetings even as expectations rise that euro zone inflation is peaking.

The European Central Bank is set to take its deposit rate up by 50 basis points to 2%, despite the euro zone economy almost certainly being in recession, as it battles inflation running at five times its target, a Reuters poll found.

It's a Super Thursday this week, with the ECB, Bank of England, and the Swiss and Norwegian central banks also expected to jack up borrowing costs. What markets are keen to find out is whether they are nearly done.

On Sunday, U.S. Treasury Secretary Janet Yellen forecast a substantial reduction in U.S. inflation in 2023, barring an unexpected shock.

Whether inflation is responding to the most aggressive Fed hiking cycle since the 1980s will be evident in this week's U.S. consumer price index report. On the corporate front, while French health group Sanofi announced it had dropped its bid for biotech company Horizon Therapeutics, the Wall Street Journal reported that Amgen is in advanced talks to buy Horizon.

Meanwhile, a consolidation is shaping up in the food delivery market as Turkish delivery company Getir bought German rival Gorillas in a deal worth $1.2 billion, merging two of the remaining companies in Europe promising groceries in minutes.

Key developments that could influence markets on Monday:

Economic data: UK October GDP and industrial output

More News
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
13 Feb 2023 17:19

European shares rise as defence stocks rally, focus on U.S. inflation data

STOXX 600 ends up 0.9%

*

Read more
3 Feb 2023 17:27

European shares log weekly gains, UK's blue-chip index hits record high

STOXX 600 up 0.3%, logs gains for second straight week

*

Read more
3 Feb 2023 11:49

Sanofi forecasts moderate profit growth on Dupixent demand

Sees "low single digit" percentage core EPS growth, FX adjusted

*

Read more
31 Jan 2023 12:26

Share buybacks in Europe as significant as in U.S.

STOXX 600 down around 1%

*

Read more
31 Jan 2023 11:30

Banks: six reasons to be overweight

STOXX 600 down 1%

*

Read more
31 Jan 2023 09:15

STOXX slides

STOXX 600 down 0.5%

*

Read more
31 Jan 2023 07:36

European shares seen lower

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

Read more
31 Jan 2023 06:56

Mind the gap

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MIND THE GAP (0656 GMT)

Read more
30 Jan 2023 20:27

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
30 Jan 2023 17:42

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
4 Jan 2023 10:51

Sanofi sees decision on Zantac dispute with Boehringer in Q1 at earliest

Arbitration decision initially expected by end of 2022

*

Read more
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.